Omass Therapeutics

Developer of therapeutics for immunological and orphan diseases

placeOxford, England, United Kingdom calendar_todayFounded 2016 groups36 employees language omass.com

Registered entities

Social engagement

Social engagement: 8.9K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

8 investors on record; lead investors include Syncona, Oxford Science Enterprises, Oxford University Innovation, Google Ventures.

Investor typeCountShare
Venture capital675%
Accelerator & incubator113%
Other / undisclosed113%

Hiring activity

Hires occasionally

2 roles tracked across 2 of the last 12 months

29 Apr 2026 · Director, Clinical Immunology

19 Mar 2026 · Computational Chemist (Senior Scientist I/Senior Scientist II)

Based on job postings tracked across public sources.

Recent activity

22 May 2026
Event
UKBiotechDay
3 Mar 2026
Event
TD Cowen 46th Annual Health Care Conference
27 Feb 2026
Milestone
anniversary
Coming soon